NEWS & VIEWS

The British healthcare system has rejected an FDA/EMA-approved treatment proven to increase survival rates for children with cancer.  NICE (National Institute for Health and Care Excellence) has rejected access to the drug across the UK, stating cost as the reason.  However, when analyzing the real expense on taxpayers, the cost amounts to less than 3 pence per person, per year, in order to give these children access to the life-saving antibody.

John London, co-founder of SKC, wanted to scream in frustration. After three years of treatment, doctors suggested that him and his wife took his daughter, Penelope, home to enjoy their remaining time together. Instead, John scanned hundreds of research abstracts seeking new treatments.